Sorafenib therapy is safe and effective, with evidence of long-lasting disease control in elderly patients with metastatic renal cell carcinoma (mRCC), according to research presented at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC). On the basis of increasing incidence of RCC with age, the objective of this retrospective, subset analysis was to assess the safety and efficacy of sorafenib in patients older than 65 years of age.

For the full story, Click Here

The American Urological Association (AUA)’s updated Prostate-Specific Antigen Best Practice Statement, first presented at the annual meeting of the AUA in April, was published in the November issue of the Journal of Urology. The statement includes the controversial guidance that the prostate-specific antigen (PSA) test should be offered to men starting at the age of 40 years, which one critic has said is not supported by any convincing evidence

For the full Story, Click Here

Drinking regular or decaffeinated coffee is associated with a reduced risk of advanced prostate cancer, new research conducted at the Channing Laboratory in Boston suggests. Men who drank the most coffee had a 59% decreased risk of either lethal or advanced prostate cancer compared with men who drank no coffee. The magnitude of risk reduction was more pronounced in men who never smoked.

For the full story, Click Here

The world’s first patient to have a malignant rectal tumor removed through the anus, thus avoiding painful abdominal incisions, was a 76-year old woman who was able to leave the Barcelona hospital where she was treated, with no complications. The surgeons are optimistic that the method can now be developed to treat a range of colorectal diseases, including cancer and diverticulitis, offering patients the benefit of fewer postoperative complications and a speedier recovery.

Spectrum Pharmaceuticals has reported that one of the two Phase III pivotal clinical trials of apaziquone has achieved enrollment target, having enrolled approximately 800 patients. The second Phase III clinical trial of apaziquone is expected to complete enrollment by the end of 2009. The apaziquone registration plan calls for two double blind, randomized Phase III clinical studies, each with 562 patients with Ta G1 or G2 low risk non-invasive bladder cancer.